🇺🇸 FDA
Pipeline program

A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis

GN43271

Phase 2 other active

Quick answer

A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis for Relapsing Multiple Sclerosis is a Phase 2 program (other) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Roche Registration Limited
Indication
Relapsing Multiple Sclerosis
Phase
Phase 2
Modality
other
Status
active

Clinical trials